Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J.T. Annema



Author of

  • +

    P2.09 - Poster Session 2 - Combined Modality (ID 213)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Combined Modality
    • Presentations: 1
    • +

      P2.09-013 - Treatment outcome in 136 patients (pts) with inoperable or irresectable non-small cell lung cancer (NSCLC), staged with PET-scan, treated with concurrent (cc) low-dose daily cisplatin and high-dose radiotherapy (ID 2722)

      09:30 - 09:30  |  Author(s): J.T. Annema

      • Abstract

      Background
      to analyse survival data, treatment results, toxicity and prognostic factors, the influence of PET-staging in the combination of daily low-dose cisplatin with high-dose radiotherapy in stage III NSCLC patients.

      Methods
      retrospective study between 2005 -2012 of PET staged patients with mainly stage III irresectable, locally advanced non small cell lung cancer. Concurent chemoradiation is given by using daily low-dose cisplatin (6mg/m2) combined with 24 fractions 2,75 Gy to a total dose of 66 Gy.

      Results
      mean follow-up 20 months, median follow-up 15 months (1, 7-88). Prognostic factors at multivariate analysis are for survival: PTV1 < 380 cc (p=0.018), ECOG scale (p=0.09). For local control: PTV1 < 380 cc (p=0.031). Our data show a linear relationship between the size of the PTV1 and survival. The median survival was 36 months and the 5-year survival rate is 33%. The incidence of distant free survival of 5 years is 27%. The local relapse free survival of 5 years is 51%.

      Conclusion
      results for survival and local control are good and show a 100% increase in 5 yr overall survival compared to our historical control series. In our data toxicity is low. In multivariate analysis a low PTV volume (<380 cc) is the only significantly favorable prognostic factor for local disease-free and overall survival. Possibilities to increase the biological radiation dose (EQD2= 74 Gy) and/or in combination with biological response modifiers should be studied in the near future. Figure 1. Overall survival for all patients Mean follow-up 20m, median follow-up 15 m (1,7-88) Figure 1 Figure 2. Overall survival stage III < 380cc and > 380cc Survival: 1=PTV1 < 380 cc, 2=PTV1>380 cc (p=0.018) Figure 2